Phibro Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>PA</div>
PAHC -- USA Stock  

USD 19.21  0.38  1.94%

Today's article will go over Phibro Animal. We will evaluate why recent Phibro Animal price moves suggest a bounce in September. Phibro Animal Health is at this time traded for 20.51. The entity has historical hype elasticity of 0.03. The average price elasticity to hype of competition is about 0.13. The firm is projected to increase in value after the next headline, with the price going to jump to 20.54. The current volatility of media hype impact on the company stock price is is way over 100 percent making price predictions on social media along less reliable. The price jump on the next news is estimated to be 0.15%, whereas the daily expected return is at this time at -0.38%. The volatility of related hype on Phibro Animal is about 832.83% with expected price after next announcement by competition of 20.64 Given the investment horizon of 30 days, the next projected press release will be in about 9 days.
Published over two months ago
View all stories for Phibro Animal | View All Stories
Will Phibro Animal (NASDAQ:PAHC) price continue slipping?
The firm's average rating is Sell from 4 analysts. Our recommendation module complements current analysts and expert consensus on Phibro Animal. It analyzes the company potential to grow using all fundamental, technical, and market related data available at the time.
The successful prediction of Phibro Animal stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Phibro Animal Health, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Phibro Animal based on Phibro Animal hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Phibro Animal's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Phibro Animal's related companies.

Use Technical Analysis to project Phibro expected Price

Phibro Animal technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Phibro Animal technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Phibro Animal trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Phibro utilizes its cash?

To perform a cash flow analysis of Phibro Animal, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Phibro Animal is receiving and how much cash it distributes out in a given period. The Phibro Animal cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Phibro Animal Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at 59.35 Million

Sale by Jack Bendheim of 10000 shares of Phibro Animal

Legal trades by Phibro Animal insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Phibro insider trading alert for sale of class a common stock by Jack Bendheim, President and CEO, on 6th of September 2020. This event was filed by Phibro Animal Health Corp with SEC on 2018-08-23. Statement of changes in beneficial ownership - SEC Form 4. Jack Bendheim currently serves as chairman of the board and presidentident, ceo of Phibro Animal Health [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

Phibro Animal reported the previous year's revenue of 818.35 M. Net Income was 36.71 M with profit before overhead, payroll, taxes, and interest of 264.62 M.

Cost of Revenue Breakdown

Phibro Animal Cost of Revenue is increasing over the years with slightly volatile fluctuation. Cost of Revenue is expected to dwindle to about 635.8 M. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Phibro Animal Cost of Revenue is projected to increase significantly based on the last few years of reporting. The past year's Cost of Revenue was at 647.88 Million
2013
2014
2015
2016
2017
2018
2019
2020
2013487.5 Million
2014515.31 Million
2015512.49 Million
2016516.04 Million
2017553.1 Million
2018563.37 Million
2019647.88 Million
2020635.84 Million

Our perspective of the current Phibro Animal rise

Information Ratio just dropped to -0.15, may suggest upcoming price decrease. As of the 26th of August, Phibro Animal holds the risk adjusted performance of (0.12), and Coefficient Of Variation of (1,152). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Phibro Animal, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Phibro Animal Health, which can be compared to its competitors. Please check Phibro Animal Health treynor ratio, and the relationship between the variance and potential upside to decide if Phibro Animal Health is priced some-what accurately, providing market reflects its current price of 20.51 per share. Given that Phibro Animal has jensen alpha of (0.40), we recommend you to check out Phibro Animal Health's recent market performance to make sure the company can sustain itself at a future point.

Our Final Take On Phibro Animal

Whereas other companies within the drug manufacturers?specialty & generic industry are still a little expensive, even after the recent corrections, Phibro Animal may offer a potential longer-term growth to investors. All things considered, as of the 26th of August 2020, our primary 30 days buy-sell recommendation on the company is Strong Hold. We believe Phibro Animal is undervalued with below average chance of financial distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Phibro Animal Health. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com